Diagnosis of Familial Combined Hyperlipidemia Based on Lipid Phenotype Expression in 32 Families
- 1 February 2002
- journal article
- other
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 22 (2) , 274-282
Abstract
Familial combined hyperlipidemia (FCH) is characterized by a variable expression of hypercholesterolemia and/or hypertriglyceridemia. We evaluated the variability in lipid phenotype expression over a 5-year period and studied factors affecting the lipid phenotype expression. A total of 32 families (299 subjects) were studied in 1994 and in 1999. Subjects were classified as having FCH when total cholesterol and/or triglyceride levels exceeded the 90th percentile adjusted for age and sex. In 1994, 93 (31%) of the 299 subjects were affected, whereas 206 (69%) of the subjects were unaffected relatives. In 1999, a diagnosis of FCH was consistent in 69 (74%) of the 93 subjects. So, 26% of the FCH subjects in 1994 showed a sporadic normolipidemic pattern (ie, total cholesterol and/or triglycerides P =0.03) and body mass index (odds ratio 1.14, 95% CI 1.05 to 1.24; P K (apoB 1461±305 versus 997±249 mg/L, respectively [ P K value −0.22±0.19 versus −0.02±0.19, respectively [ P K value show less variability in time and are more consistently associated with FCH, inasmuch as affected FCH subjects, compared with the unaffected relatives, persistently show a higher apoB level and a lower value of parameter K , reflecting small dense LDL, even when they present a sporadic normolipidemic pattern. In conclusion, our results emphasize the need for reevaluation of the diagnostic criteria for FCH. We demonstrate that apoB and small dense LDL are attractive new candidates for defining FCH. Further studies are indicated to evaluate the role of apoB and small dense LDL as diagnostic criteria for FCH.Keywords
This publication has 21 references indexed in Scilit:
- The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemiaAtherosclerosis, 2000
- A Genome Scan for Familial Combined Hyperlipidemia Reveals Evidence of Linkage with a Locus on Chromosome 11The American Journal of Human Genetics, 1999
- A Common Genetic Mechanism Determines Plasma Apolipoprotein B Levels and Dense LDL Subfraction Distribution in Familial Combined HyperlipidemiaThe American Journal of Human Genetics, 1998
- Phenotype expression in familial combined hyperlipidemiaAtherosclerosis, 1997
- Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemiaAtherosclerosis, 1996
- Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides*European Journal of Clinical Investigation, 1994
- Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience)The American Journal of Cardiology, 1992
- Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
- Plasma lipoproteins, apolipoproteins, and triglyceride metabolism in familial hypertriglyceridemia.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1986
- Hyperlipidemia in Coronary Heart Disease II. GENETIC ANALYSIS OF LIPID LEVELS IN 176 FAMILIES AND DELINEATION OF A NEW INHERITED DISORDER, COMBINED HYPERLIPIDEMIAJournal of Clinical Investigation, 1973